India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 ...

FDA finds benzene contamination, Tronox to close a pigment plant, Sofinnova launches a European biotech fund, and more ...

Brainomix, a company pioneering AI-powered imaging tools in stroke and lung fibrosis, today announced the completion of a £14M ($18M) Series C investment round. The round is co-led by prominent ...

The new initiative aims to improve early detection by increasing access to screening in communities where accessing care is more difficult.

The study, published in the prestigious journal EMBO Journal, reveals why some tumors escape the immune system, and offers a ...

Boehringer Ingelheim has moved a step closer to getting ... The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Ofev (nintedanib) for the treatment of adults ...

B.C. government B.C. Supreme Court opioid case against pharmaceutical companies can move ahead, appeal court rules in ...

The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...

Tempus AI's financials have significantly improved, with positive cash flow expected next quarter. Read why TEM stock is a ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

As a drugmaker depending heavily on sales of both branded and non-branded products, Teva has said that it is uniquely affected by how medicines are selected for the Medicare drug price negotiation | ...

Boehringer Ingelheim has taken an option on a family ... that spans both pharmacological and digital therapeutic (DTx) products. Leading the charge for new drug therapies is iclepertin (also ...